Related Experiment Video

Updated: Jun 7, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K

TIPE2 inhibits melanoma progression through MEK/ERK signaling

Xin Gao1, Yan Li2, Congcong Wang2

  • 1School of Clinical Medicine, Weifang Medical University, Weifang, China.

Scientific Reports
|November 12, 2024
PubMed

Insights

Tumor Inhibitor Peptide 2 (TIPE2) is downregulated in melanoma. Overexpressing TIPE2 suppresses melanoma cell proliferation and migration, suggesting TIPE2 as a potential therapeutic target for melanoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Tumor Inhibitor Peptide 2 (TIPE2) has been implicated in cancer development.
  • The specific role of TIPE2 in melanoma pathogenesis remains underexplored.

Purpose of the Study:

  • To investigate the functional role and mechanism of TIPE2 in melanoma development.
  • To assess TIPE2 expression levels in melanoma tissues compared to adjacent non-cancerous tissues.

Main Methods:

  • Quantitative analysis of TIPE2 expression in paracarcinoma and melanoma tissues.
  • In vitro studies using melanoma cell lines to assess proliferation, colony formation, and migration upon TIPE2 overexpression (CCK8 assay, colony formation assay, wound healing assay).
  • In vivo tumor formation studies in nude mice and immunohistochemistry to validate findings and assess pathway involvement (MEK/ERK phosphorylation).

Main Results:

  • TIPE2 expression was significantly downregulated in melanoma tissues compared to paracarcinoma tissues.
  • Overexpression of TIPE2 markedly inhibited melanoma cell proliferation, colony formation, and migration in vitro.
  • In vivo experiments confirmed that TIPE2 overexpression suppressed tumor formation and reduced MEK/ERK phosphorylation.

Conclusions:

  • TIPE2 acts as a suppressor of melanoma cell proliferation and migration.
  • The MEK/ERK signaling pathway is potentially regulated by TIPE2 in melanoma.
  • TIPE2 represents a promising therapeutic target for inhibiting melanoma growth.
Keywords:
ERKMelanomaMigrationProliferationTIPE2

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

15.7K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K